The diagnostics company easily topped Q4 revenue and earnings expectations. But the bottom-line beat came with an asterisk.
News & Analysis: Exact Sciences
EXAS earnings call for the period ending December 31, 2019.
While revenue figures are up substantially, they fell a little short of Wall Street's expectations.
This developer of diagnostic tests will continue to drive the personalization of cancer treatment.
Genome testing is exploding on a global level; these companies are saving lives and making money.
One just wrapped up a multi-billion-dollar acquisition while the other elected to remain independent.
After a successful 2019, the diagnostics company faces new growth opportunities with both Cologuard and its cancer-diagnostics pipeline.
Potential competitors for its colon cancer test Cologuard aren't ready for prime time.
Sales of its legacy business were up 61% year over over while revenue from recently-acquired Genomic Health grew 13%.
Which biotech was a 37-bagger?